Articles > Popular publications > PR Newswire press releases > October-December 1987 > Thursday, October 15

Article: Cambridge BioScience announces distribution agreement with Baxter Healthcare for Recombigen(tm) AIDS diagnostic products.

Article from:
PR Newswire
Article date:
October 15, 1987
Copyright

CAMBRIDGE BIOSCIENCE ANNOUNCES DISTRIBUTION AGREEMENT WITH

BAXTER HEALTHCARE FOR RECOMBIGEN (TM) AIDS DIAGNOSTIC PRODUCTS

WORCESTER, Mass., Oct. 15 /PRNewswire/ -- Cambridge BioScience Corporation (NASDAQ: CBCX) announced today a worldwide exclusive distribution agreement with the Pandex Division of Baxter Healthcare Corporation.

Under this agreement, Pandex and other affiliates of Baxter will distribue the CBC-manufactured Recombigen(TM) AIDS diagnostic products under the Baxter/Pandex label.

The Recombigen (TM) products utilize a novel recombinant protein, rather than materials from the AIDS (HIV) virus, which can detect HIV ...

Read all of this article with a FREE trial

Related newspaper, magazine, and journal articles:

Article: Cambridge BioScience announces two GP120 protein ...
PR Newswire;  February 20, 1990 ;     667 words ... ... PRNewswire/ -- Cambridge BioScience Corporation ... diagnostic use. Cambridge BioScience is the exclusive ... Beckman, and Baxter Healthcare Corporation ... announcement, Cambridge BioScience Vice President ...

Article: Cambridge BioScience files clinical data with FDA ...
PR Newswire;  April 25, 1988 ;     669 words ... ... PRNewswire/ -- Cambridge BioScience Corporation ... product line, Cambridge BioScience, in conjunction ... marketing partner Baxter Healthcare and affiliates ... later this year. Cambridge BioScience is a biotechnology ...

Article: Cambridge BioScience files clinical data with FDA ...
PR Newswire;  February 11, 1988 ;     700+ words ... ... PRNewswire/ -- Cambridge BioScience Corporation ... Pandex Division of Baxter Healthcare Corporation ... marketing partner Baxter Healthcare (Pandex Division ... foreign countries. Cambridge BioScience is a biotechnology ...

Article: Cambridge Bioscience begins direct marketing of ...
PR Newswire;  March 9, 1990 ;     700+ words ...CAMBRIDGE BIOSCIENCE BEGINS DIRECT MARKETING ... PRNewswire/ -- Cambridge BioScience Corporation (NASDAQ ... announcement means that Baxter Healthcare Corporation will ... our bottom line." Cambridge BioScience has six people dedicated ...

Article: Cambridge BioScience files infringement suit on ...
PR Newswire;  January 3, 1990 ;     700+ words ... ... sublicense from Cambridge BioScience. Harvard University ... exclusively to Cambridge BioScience, which financially ... Diagnostics Pasteur, Baxter Healthcare Corporation ... AIDS patients. Cambridge BioScience initiated the ...

Article: Cambridge BioScience expects losses in third and ...
PR Newswire;  September 21, 1989 ;     700+ words ... ... PRNewswire/ -- Cambridge BioScience Corporation ... executive officer of Cambridge BioScience, cited slower ... division, and Baxter Healthcare Corp. On a broader ... patent licensing. Cambridge BioScience has granted several ...

Article: Four sublicenses for gp120 granted by Cambridge ...
PR Newswire;  February 7, 1989 ;     700+ words ... ... gp120 GRANTED BY CAMBRIDGE BIOSCIENCE WORCESTER, Mass ... PRNewswire/ -- Cambridge BioScience, (NASDAQ: CBCX ... bank market, Baxter Healthcare Corporation ... 1 AIDS virus. Cambridge BioScience received the exclusive ...

Article: Cambridge BioScience announces gp120 sublicense to ...
PR Newswire;  March 27, 1990 ;     700+ words ... ... PRNewswire/ -- Cambridge BioScience Corporation ... announcement, Cambridge BioScience President Patrick ... SmithKline Beckman, Baxter Healthcare Corporation ... diagnostics. Cambridge BioScience Corporation is ...

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!

Find articles, research, and archives